ESR1 and neoplasm: Previous research in our lab and others has assessed ERα/PR crosstalk and found that, in ERα+/PR+ treatment-naïve cells, combined modulation of both receptors promoted tumor regression, and chromatin binding profiles indicated that PR alters ERα-associated gene expression in the ERα WT context8–11.